2 weeks Ago By Defense World Staff
Legal & General Group Plc increased its position in Elevance Health, Inc. ( NYSE:ELV – Free Report ) by 2.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission.
The firm owned 2,247,091 shares of the company’s stock after buying an additional 64,376 shares during the quarter. Legal & General Group Plc owned about 0.97% of Elevance Health worth $1,217,607,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Lighthouse Investment Partners LLC lifted its stake in shares of Elevance Health by 14.7% in the 2nd quarter.
Lighthouse Investment Partners LLC now owns 13,363 shares of the company’s stock valued at $7,241,000 after purchasing an additional 1,712 shares in the last quarter. Mackenzie Financial Corp raised its holdings in Elevance Health by 1.1% in the second quarter.
Mackenzie Financial Corp now owns 73,964 shares of the company’s stock valued at $40,078,000 after buying an additional 773 shares during the period. MBB Public Markets I LLC acquired a new position in Elevance Health during the second quarter valued at approximately $8,987,000. Dark Forest Capital Management LP acquired a new position in Elevance Health during the second quarter valued at approximately $1,023,000.
Finally, Daymark Wealth Partners LLC grew its stake in Elevance Health by 3.1% during the second quarter. Daymark Wealth Partners LLC now owns 2,120 shares of the company’s stock worth $1,149,000 after buying an additional 64 shares during the period.
Institutional investors and hedge funds own 89.24% of the company’s stock. Analyst Upgrades and Downgrades ELV has been the topic of several recent research reports.
JPMorgan Chase & Co. lifted their target price on shares of Elevance Health from $628.00 to $631.
00 and gave the company an “overweight” rating in a report on Thursday, May 30th. Wells Fargo & Company reduced their price objective on Elevance Health from $600.00 to $593.
00 and set an “overweight” rating on the stock in a research note on Monday, July 22nd. Bank of America reiterated a “neutral” rating and issued a $530.00 target price (down previously from $646.
00) on shares of Elevance Health in a research note on Thursday, July 18th. Robert W. Baird initiated coverage on Elevance Health in a research report on Thursday, May 30th.
They set an “outperform” rating and a $649.00 price target on the stock. Finally, TD Cowen lowered their price objective on shares of Elevance Health from $624.
00 to $589.00 and set a “buy” rating for the company in a research report on Friday, July 19th. One equities research analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company.
According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $604.29. Elevance Health Price Performance Shares of ELV stock opened at $520.
28 on Friday. The firm has a fifty day moving average of $536.06 and a two-hundred day moving average of $529.
74. The firm has a market cap of $120.92 billion, a P/E ratio of 19.
66, a P/E/G ratio of 1.17 and a beta of 0.82.
Elevance Health, Inc. has a 1-year low of $431.38 and a 1-year high of $567.
26. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.
49 and a quick ratio of 1.49. Elevance Health ( NYSE:ELV – Get Free Report ) last announced its quarterly earnings data on Wednesday, July 17th.
The company reported $10.12 earnings per share for the quarter, beating the consensus estimate of $9.99 by $0.
13. Elevance Health had a return on equity of 20.64% and a net margin of 3.
89%. The firm had revenue of $43.22 billion during the quarter, compared to analyst estimates of $42.
99 billion. During the same period in the previous year, the company earned $9.04 earnings per share.
Elevance Health’s quarterly revenue was down .4% on a year-over-year basis. As a group, research analysts anticipate that Elevance Health, Inc.
will post 37.25 earnings per share for the current fiscal year. Elevance Health Announces Dividend The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 25th.
Investors of record on Tuesday, September 10th were paid a dividend of $1.63 per share. This represents a $6.
52 annualized dividend and a yield of 1.25%. The ex-dividend date of this dividend was Tuesday, September 10th.
Elevance Health’s dividend payout ratio (DPR) is presently 24.64%. Insiders Place Their Bets In other Elevance Health news, Director Robert L.
Dixon, Jr. sold 305 shares of the stock in a transaction on Friday, July 19th. The shares were sold at an average price of $506.
76, for a total transaction of $154,561.80. Following the sale, the director now directly owns 9,721 shares of the company’s stock, valued at $4,926,213.
96. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website . In other news, Director Robert L.
Dixon, Jr. sold 305 shares of the company’s stock in a transaction that occurred on Friday, July 19th. The stock was sold at an average price of $506.
76, for a total transaction of $154,561.80. Following the completion of the transaction, the director now directly owns 9,721 shares of the company’s stock, valued at $4,926,213.
96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website . Also, Director Ramiro G.
Peru sold 753 shares of the firm’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $531.52, for a total value of $400,234.
56. Following the completion of the sale, the director now directly owns 8,744 shares in the company, valued at approximately $4,647,610.88.
The disclosure for this sale can be found here . Insiders sold a total of 35,058 shares of company stock valued at $17,588,116 over the last 90 days. 0.
35% of the stock is owned by company insiders. About Elevance Health ( Free Report ) Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other.
It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. Featured Articles Five stocks we like better than Elevance Health What Investors Need to Know About Upcoming IPOs REITs on the Rise After Rate Cuts: Where to Invest Now How to Use High Beta Stocks to Maximize Your Investing Profits Is Viking Therapeutics Ready For Another Surge? What is an Earnings Surprise? AI Boom and Rate Cuts Boost Utility Stocks: Best Growth Picks Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc.
( NYSE:ELV – Free Report ). Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter .
.
